{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:31:29Z","timestamp":1782930689953,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,10]],"date-time":"2018-06-10T00:00:00Z","timestamp":1528588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,10]],"date-time":"2018-06-10T00:00:00Z","timestamp":1528588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc."},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Bipolar Disord"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The long-acting injectable antipsychotic aripiprazole once-monthly 400\u00a0mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance treatment for BP-I.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This open-label multicenter study evaluated the effectiveness of AOM 400 as maintenance treatment for BP-I by assessing safety and tolerability (primary objective) and efficacy (secondary objective). The study enrolled AOM 400-naive (\u201cde novo\u201d) patients as well as AOM 400-experienced (\u201crollover\u201d) patients with BP-I from a lead-in randomized, placebo-controlled clinical trial that demonstrated the efficacy of AOM 400 in the maintenance treatment of BP-I (Calabrese et al. in J Clin Psychiatry 78:324\u2013331, 2017). Safety variables included frequency and severity of treatment-emergent adverse events (TEAEs) and TEAEs resulting in study discontinuation. Efficacy was assessed by the proportion of patients maintaining stability throughout the maintenance phase, as well as mean changes from baseline in Young Mania Rating Scale (YMRS), Montgomery\u2013Asberg Depression Rating Scale, and Clinical Global Impressions for Bipolar Disorder\u2013Severity of Illness Scale (CGI-BP-S) total scores. Patient acceptability and tolerability of treatment was assessed using the Patient Satisfaction with Medication Questionnaire-Modified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 464 patients entering the maintenance phase, 379 (82%) were de novo and 85 (18%) were rollover. TEAEs were more common in de novo than rollover patients. The overall discontinuation rate due to TEAEs was 10.3% (48\/464). Improvements in YMRS and CGI-BP-S total scores were maintained during the study, and the vast majority of both de novo (87.0%) and rollover (97.6%) patients maintained stability through their last visit. Overall, the need for rescue medication during the maintenance phase was minimal (&lt;\u200910% of patients). Patient satisfaction levels were high, with both de novo and rollover patients rating the side effect burden of AOM 400 as greatly improved relative to previous medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>AOM 400 was safe, effective, and well tolerated by both de novo and AOM 400-experienced patients with BP-I for long-term maintenance treatment.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01710709?term=NCT01710709&amp;rank=1\">NCT01710709<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40345-018-0122-z","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T14:51:31Z","timestamp":1525877491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study"],"prefix":"10.1186","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01710709","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Joseph R.","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Madera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Ottinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Amatniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,10]]},"reference":[{"key":"122_CR1","volume-title":"Full prescribing information","author":"Abilify Maintena\u00ae US (aripiprazole)","year":"2016","unstructured":"Abilify Maintena\u00ae US (aripiprazole). Full prescribing information. Tokyo: Otsuka Pharmaceutical Co., Ltd.; 2016."},{"key":"122_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and statistical manual of mental disorders, fourth edition, text revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000."},{"key":"122_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry Suppl. 1989;154:672\u20136.","journal-title":"Br J Psychiatry Suppl"},{"issue":"5","key":"122_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198\u2013219.","journal-title":"Ther Adv Psychopharmacol."},{"key":"122_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4088\/JCP.16m11201","volume":"78","author":"JR Calabrese","year":"2017","unstructured":"Calabrese JR, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017;78:324\u201331.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"122_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737175.2017.1371014","volume":"17","author":"L Citrome","year":"2017","unstructured":"Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Rev Neurother. 2017;17(10):1029\u201343.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"122_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119\u201336.","journal-title":"World Psychiatry."},{"issue":"5","key":"122_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1517\/14740338.2014.906579","volume":"13","author":"M De Hert","year":"2014","unstructured":"De Hert M, Detraux J, Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf. 2014;13(5):605\u201324.","journal-title":"Expert Opin Drug Saf."},{"issue":"10027","key":"122_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","volume":"387","author":"I Grande","year":"2016","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561\u201372.","journal-title":"Lancet"},{"key":"122_CR10","first-page":"534","volume-title":"Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 534\u20137."},{"issue":"6","key":"122_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.pnpbp.2007.04.017","volume":"31","author":"C Han","year":"2007","unstructured":"Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1219\u201323.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"122_CR12","unstructured":"International Conference on Harmonisation. E6: Good clinical practice: consolidated guideline. http:\/\/www.ich.org. Accessed July 26 2016."},{"issue":"2","key":"122_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1185\/03007999909113374","volume":"15","author":"A Kalali","year":"1999","unstructured":"Kalali A. Patient satisfaction with, and acceptability of, atypical antipsychotics. Curr Med Res Opin. 1999;15(2):135\u20137.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"122_CR14","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.10255","volume":"17","author":"JH Kim","year":"2002","unstructured":"Kim JH, Jung HY, Kang UG, Jeong SH, Ahn YM, Byun HJ, et al. Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord. 2002;17(6):1354\u20139.","journal-title":"Mov Disord"},{"issue":"9","key":"122_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyw038","volume":"19","author":"T Kishi","year":"2016","unstructured":"Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(9):1\u201310.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"122_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","volume":"74","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957\u201365.","journal-title":"J Clin Psychiatry"},{"key":"122_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jad.2017.02.012","volume":"213","author":"L Lindstr\u00f6m","year":"2017","unstructured":"Lindstr\u00f6m L, Lindstr\u00f6m E, Nilsson M, H\u00f6istad M. Maintenance therapy with second generation antipsychotics for bipolar disorder\u2014a systematic review and meta-analysis. J Affect Disord. 2017;213:138\u201350.","journal-title":"J Affect Disord"},{"issue":"8","key":"122_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1399-5618.2009.00761.x","volume":"11","author":"W Macfadden","year":"2009","unstructured":"Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827\u201339.","journal-title":"Bipolar Disord"},{"issue":"2","key":"122_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1176\/appi.ajp.161.2.262","volume":"161","author":"A Martinez-Aran","year":"2004","unstructured":"Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004;161(2):262\u201370.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"122_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jad.2008.10.023","volume":"116","author":"DJ Martino","year":"2009","unstructured":"Martino DJ, Marengo E, Igoa A, Scapola M, Ais ED, Perinot L, et al. Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1\u00a0year follow-up study. J Affect Disord. 2009;116(1\u20132):37\u201342.","journal-title":"J Affect Disord"},{"key":"122_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/NDT.S13876","volume":"7","author":"RS McIntyre","year":"2011","unstructured":"McIntyre RS, Yoon J, Jerrell JM, Liauw SS. Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatr Dis Treat. 2011;7:319\u201323.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"122_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry Suppl. 1979;134:382\u20139.","journal-title":"Br J Psychiatry Suppl"},{"key":"122_CR23","unstructured":"Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Columbia Suicide Severity Rating Scale. 2009. http:\/\/cssrs.columbia.edu\/docs\/C-SSRS_1_14_09_Baseline.pdf. Accessed 19 Apr 2016."},{"issue":"2","key":"122_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","volume":"68","author":"JA Quiroz","year":"2010","unstructured":"Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156\u201362.","journal-title":"Biol Psychiatry"},{"key":"122_CR25","volume-title":"Full prescribing information","author":"Risperdal Consta\u00ae (risperidone long-acting injection)","year":"2016","unstructured":"Risperdal Consta\u00ae (risperidone long-acting injection). Full prescribing information. Titusville: Janssen Pharmaceuticals, Inc.; 2016."},{"issue":"suppl 20","key":"122_CR26","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22\u201333.","journal-title":"J Clin Psychiatry"},{"key":"122_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"3","key":"122_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/15748847113089990051","volume":"9","author":"S Spanarello","year":"2014","unstructured":"Spanarello S, Ferla TL. The pharmacokinetics of long-acting antipsychotic medications. Current Clinical Pharmacology. 2014;9(3):310\u20137.","journal-title":"Current Clinical Pharmacology."},{"issue":"3","key":"122_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","volume":"73","author":"MK Spearing","year":"1997","unstructured":"Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159\u201371.","journal-title":"Psychiatry Res"},{"issue":"8","key":"122_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015;72(8):822\u20139.","journal-title":"JAMA Psychiatry."},{"issue":"3","key":"122_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339\u201347.","journal-title":"World Psychiatry."},{"key":"122_CR32","volume-title":"Practice guideline for the treatment of patients with bipolar disorder","author":"Work Group on Bipolar Disorder","year":"2002","unstructured":"Work Group on Bipolar Disorder. Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2002.","edition":"2"},{"key":"122_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry Suppl. 1978;133:429\u201335.","journal-title":"Br J Psychiatry Suppl"}],"container-title":["International Journal of Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-018-0122-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40345-018-0122-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-018-0122-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:40:54Z","timestamp":1628617254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalbipolardisorders.springeropen.com\/articles\/10.1186\/s40345-018-0122-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1186\/s40345-018-0122-z","relation":{},"ISSN":["2194-7511"],"issn-type":[{"value":"2194-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,10]]},"assertion":[{"value":"24 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}